Skip to Content
  1. All products
  2. Recovery & Regeneration
  3. KLOW (GHK-CU/TB-500/BPC-157/KPV)
  4. Recovery & Regeneration
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
KLOW (GHK-CU/TB-500/BPC-157/KPV)

KLOW (GHK-CU/TB-500/BPC-157/KPV)

Blend · Subcutaneous, Topical, Intradermal Refrigerate after reconstitution (2-8°C). 60 days if sterile integrity maintained. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 141.00 $ 141.00

Format
⚗ blend
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

Tissue repair, systemic recovery, angiogenesis, collagen production, anti-aging, inflammation modulation, gut health support

El Klow Blend combina BPC-157, TB-500, GHK-CU y KPV para una regeneración de espectro completo. BPC-157 proporciona reparación localizada de tejido y tubo digestivo. TB-500 brinda recuperación sistémica y angiogénesis. GHK-CU apoya el colágeno, la piel y los efectos antienvejecimiento. KPV proporciona inflamación y modulación inmune, especialmente la relacionada con el intestino.

Clinical Indications
Post-procedure recovery protocolsConnective tissue and skin repair supportInflammation and healing pathway support
Recommended Stacking Protocols
✓
CJC-1295 + Ipamorelin
Increases endogenous GH output → amplified collagen and repair
✓
Thymosin Alpha-1
Adds immune stability and reduces auto-inflammatory load
✓
Epithalon
Cellular anti-aging support during long protocols
Blend Components
Component Amount (mg)
BPC-157 10.67
TB-500 10.67
GHK-Cu 53.33
KPV 5.33

Mechanism of Action - Recovery & Tissue Repair Pathway

Targeted Signaling
Supports protocol objectives for KLOW (GHK-CU/TB-500/BPC-157/KPV).
Clinical Modulation
Allows dose and schedule adjustments by response.
Outcome Tracking
Pairs with clinician monitoring for iterative optimization.
Starting Dose
Low initial dose
Initiation phase for tolerance and baseline response.
Titration
Escalate by protocol
Maintenance Range
Maintain physician-directed target
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Frecuencia:1-2 veces al día dependiendo de los objetivos

Momento:Mejor con el estómago vacío (30 min antes de las comidas o 90 min después)

Period Dose Phase Clinical Notes
Weeks 1-2 Initial phase initiation Begin conservatively and monitor tolerance.
Weeks 3-6 Escalation phase escalation Increase per protocol if tolerated.
Week 7+ Maintenance phase maintenance Maintain target dose and reassess monthly.
Preparation Protocol
  1. Vía: Subcutánea, intradérmica o tópica (diluida).
  2. Utilice una jeringa de insulina de 0,5 ml (100 unidades = 1 ml).
  3. Refrigerar después de la reconstitución (2-8°C).60 días si se mantiene la integridad estéril.
1
Inspect vial
Confirm vial integrity, lot, and expiration before use.
2
Aseptic reconstitution
Disinfect stopper and add bacteriostatic water slowly.
3
Gentle dissolution
Swirl gently until the solution is clear and homogeneous.
4
Prepare dose
Draw dose according to reconstitution conversion guidance.
Reconstitution & Dosing Guide

No reconstitution guide available for this strength.

Identity
  • Product Name: KLOW (GHK-CU/TB-500/BPC-157/KPV)
  • Product Type: Blend | Subcutaneous, Intradermal, or Topical
  • Strength Options: 50/10/10/10 mg
  • Components: BPC-157 + TB-500 + GHK-Cu + KPV
Quality & Purity
  • Purity: >= 99%
  • Sterility: Aseptic handling required
  • Purity: 99%+
Storage & Handling
  • Storage: 2-8 C refrigerated
  • Handling: Avoid heat, shaking, and direct light
  • Storage: Refrigerate after reconstitution (2-8°C). 60 days if sterile.

Timing: Timing-Bestonemptystomach(30 minbeforemealsor90 minafter)

Storage: Refrigerate after reconstitution (2-8°C). 60 days if sterile integrity maintained.

Frequency: Frequency:1x daily(anti-aging/maintenance) or 2x daily(active recovery,gut support).

Cycle: .Cycle:6-10weeks. .Cycle:8-12weeks(extendableforchronicconditions).

Injection Sites: Route-Subcutaneous,intradermal,ortopical(diluted). InjectionSites:SubQtoabdomen,or localized area ofinflammation/injury.Can alsobemicro-injected InjectionSites:Abdomenorlocalizedareaofconcern.